# Automated vs Manual Flow-cytometry Gating for Measurable Residual Disease in Acute Myeloid Leukaemia (DUALFLOW)

> **NCT07269067** · — · NOT_YET_RECRUITING · sponsor: **University Hospital, Bordeaux** · enrollment: 60 (estimated)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DIAGNOSTIC_TEST:** Conventional gating
- **DIAGNOSTIC_TEST:** Automated gating

## Key facts

- **NCT ID:** NCT07269067
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07269067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07269067, "Automated vs Manual Flow-cytometry Gating for Measurable Residual Disease in Acute Myeloid Leukaemia (DUALFLOW)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07269067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*